Shots:

• Bavarian Nordic plans to initiate a P-III study for its RSV vaccine MVA-BN in H1’22 which is subject to successfully raising equity capital
• In Sep’21, company reported positive results of P-II human challenge study, showing a statistically significant reduction in viral load in vaccinated vs placebo. MVA-BN vaccine showed an efficacy of up to 79% in preventing RSV infections
• Bavarian Nordic in collaboration with an undisclosed CRO plans to initiate P-III study where they plan to recruit n=20,000 across geographies with follow-up planned for 2023-24

Ref: Bavarian | Image: Bavarian